OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED PHASE 2 TRIAL OF PF299804 VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF CHEMOTHERAPY

被引：0
|
作者：
Boyer, Michael [1 ]
Blackhall, Fiona H. [2 ]
Barrios, Carlos H.
Frank, Richard C. [3 ]
Heo, Deo Seog [4 ]
Park, Keunchil [5 ]
Rosell, Rafael [6 ]
Talbot, Denis C. [7 ]
Taylor, Ian C.
Liang, Jane
Campbell, Alicyn K.
O'Connell, Joseph
Ramalingam, Suresh [8 ]
机构：
[1] Sydney Canc Ctr, Sydney, NSW, Australia
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Norwalk Hosp, Norwalk, CT USA
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hem Onc,Dept Med, Seoul, South Korea
[6] Catalan Inst Oncol, Girona, Catalonia, Spain
[7] Oxford Oncol Ctr, Oxford, England
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
PF-00299804; Overall survival; Non-small cell lung cancer; EGFR TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S318 / S319
页数：2
相关论文
共 50 条
  • [21] Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
    Kim, Lucia
    Saieg, Mauro
    Di Maio, Massimo
    Gallo, Ciro
    Butts, Charles
    Ciardiello, Fortunato
    Feld, Ronald
    Cheng, Dengxiao
    Gebbia, Vittorio
    Burgio, Marco Angelo
    Alam, Yasmin
    Signoriello, Simona
    Rossi, Antonio
    Leighl, Natasha
    Maione, Paolo
    Morabito, Alessandro
    Liu, Geoffrey
    Tsao, Ming-Sound
    Perrone, Francesco
    Gridelli, Cesare
    ONCOTARGET, 2017, 8 (34) : 57528 - 57536
  • [22] Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Pluzanska, A
    Szczesna, A
    Kaukel, E
    Roubec, J
    Brennscheidt, U
    De Rosa, F
    Mueller, B
    Von Pawel, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 619S - 619S
  • [23] Erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC): Results of a phase II open-label trial
    Piantedosi, F., V
    Gilli, M.
    Caputo, F.
    Casale, B.
    Bianco, A.
    Dericoloso, A.
    Pontillo, A.
    Crispino, C.
    Giuliarini, G.
    Hengheller, M.
    Chianca, P.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 26
  • [24] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy:: FISH results.
    Felip, E.
    Rojo, F.
    Reck, M.
    Heller, A.
    Klughammer, B.
    Maacke, H.
    Möcks, J.
    Brennscheidt, U.
    Gatzemeier, U.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 404S - 404S
  • [25] Adjuvant chemotherapy improves overall and disease-free survival in non-small cell lung cancer (NSCLC): results of the IALT trial
    Le Chevalier, T
    Kozlowski, M
    Pignon, JP
    Bergman, B
    Orlowski, T
    Pirker, R
    Le Pechoux, C
    Tarayre, M
    Dunant, A
    LUNG CANCER, 2004, 46 : S13 - S13
  • [26] Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
    Soussi, Ghassen
    Racil, Hajer
    Bacha, Saoussen
    Rouhou, Sana Cheikh
    Zidi, Asma
    Ayadi, Aida
    Chaouch, Nawel
    Chabbou, Abdellatif
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [27] Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2.
    Lilenbaum, R.
    Axerold, R.
    Thomas, S.
    Dowlati, A.
    Seigel, L.
    Albert, D.
    Van Duym, C.
    Bodkin, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 369S - 369S
  • [28] The impact of alternative dosing regimens on overall survival (OS) in the treatment of non small cell lung cancer (NSCLC) with Erlotinib
    Pembroke, C.
    Pembroke, T.
    Vigneswaran, V.
    Rowley, K.
    LUNG CANCER, 2012, 75 : S10 - S10
  • [29] ARCHER: A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY OF DACOMITINIB (PF-00299804) VERSUS ERLOTINIB FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC)
    Antic, V.
    Boyer, M.
    Janne, P.
    Mok, T.
    O'Byrne, K.
    Paz-Ares, L.
    Ramalingam, S. S.
    Liang, J.
    Taylor, I.
    Letrent, S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S67 - S67
  • [30] Quality of life and survival in patients receiving chemotherapy for advanced non-small cell lung cancer (NSCLC)
    St-Pierre, D. M.
    Kreisman, H.
    Kasymjanova, G.
    Agulnik, J. S.
    Swanson, T.
    Pepe, C.
    Lajeunesse, L.
    Gagne, S.
    Dajczman, E.
    Pereira, L.
    Small, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345